Phase 1b/3 Multicenter Study of Oprozomib, Pomalidomide, and Dexamethasone in Primary Refractory or Relapsed and Refractory Multiple Myeloma Subjects
Phase of Trial: Phase I
Latest Information Update: 08 May 2019
Price : $35 *
At a glance
- Drugs Oprozomib (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen; Onyx Pharmaceuticals
- 03 May 2019 Status changed from active, no longer recruiting to completed.
- 12 Feb 2019 Planned End Date changed from 28 Feb 2019 to 30 Apr 2019.
- 12 Feb 2019 Planned primary completion date changed from 28 Feb 2019 to 30 Apr 2019.